Pre-clinical efficacy of PU-H71, a novel HSP90 inhibitor, alone and in combination with bortezomib in Ewing sarcoma

Molecular Oncology

Volumn 8, Issue 2, 2014, Pages 323-336

  Ambati, Srikanth R ^a   Lopes, Eloisi Caldas ^a   Kosugi, Kohji ^a   Mony, Ullas ^a   Zehir, Ahmet ^a   Shah, Smit K ^a   Taldone, Tony ^a   Moreira, Andre L ^a   Meyers, Paul A ^a   Chiosis, Gabriela ^a   Moore, Malcolm A S ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Bortezomib; Ewing sarcoma; HSP90 inhibitor; PU H71

Indexed keywords

BORTEZOMIB; CASPASE 3; CASPASE 7; CD31 ANTIGEN; CHAPERONE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORESCEIN ISOTHIOCYANATE; HEAT SHOCK PROTEIN 90 INHIBITOR; HYBRID PROTEIN; LIPOCORTIN 5; PROTEASOME; PROTEIN BAD; PU H71; RAF PROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TISSUE CULTURE MEDIUM; UBIQUITINATED PROTEIN; UNCLASSIFIED DRUG; VINCRISTINE;

AKT KINASE ASSAY; ANIMAL EXPERIMENT; ARTICLE; BENIGN MESENCHYMAL STROMAL CELL; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURVIVAL; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G2 PHASE; CELL CYCLE S PHASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL VIABILITY; CLONOGENESIS; CLONOGENIC ASSAY; COMPARATIVE STUDY; DENSITOMETRY; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG SCREENING; EWING SARCOMA; FLOW CYTOMETRY; G2 PHASE CELL CYCLE CHECKPOINT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; IC 50; IMMUNOBLOTTING; IN VIVO STUDY; LUMINESCENCE; MESENCHYMAL STROMA CELL; MOUSE; NONHUMAN; ONCOGENE C KIT; ONCOGENE C MYC; PRECIPITATION; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN EXPRESSION; PROTEIN MICROARRAY; REVERSE PHASE PROTEIN ARRAY; TUMOR GROWTH; TUMOR VOLUME; VASCULARIZATION; WESTERN BLOTTING;

MUS; MUS MUSCULUS;

BORTEZOMIB; EWING SARCOMA; HSP90 INHIBITOR; PU-H71;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZODIOXOLES; BONE NEOPLASMS; BORONIC ACIDS; CELL LINE, TUMOR; FEMALE; HSP90 HEAT-SHOCK PROTEINS; HUMANS; MALE; MICE; MICE, NUDE; NEOPLASMS, EXPERIMENTAL; PURINES; PYRAZINES; SARCOMA, EWING; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84894327787     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2013.12.005     Document Type: Article

References (50)

1. Bagatell R., Beliakoff J., David C.L., Marron M.T., Whitesell L. Hsp90 inhibitors deplete key anti-apoptotic proteins in pediatric solid tumor cells and demonstrate synergistic anticancer activity with cisplatin. Int. J. Cancer 2005, 113:179-188.
2. Bagatell R., Gore L., Egorin M.J., Ho R., Heller G., Boucher N., Zuhowski E.G., Whitlock J.A., Hunger S.P., Narendran A., Katzenstein H.M., Arceci R.J., Boklan J., Herzog C.E., Whitesell L., Ivy S.P., Trippett T.M. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin. Cancer Res. 2007, 13:1783-1788.
3. Bailly R.A., Bosselut R., Zucman J., Cormier F., Delattre O., Roussel M., Thomas G., Ghysdael J. DNA-binding and transcriptional activation properties of the EWS-FLI-1 fusion protein resulting from the t(11;22) translocation in Ewing sarcoma. Mol. Cell. Biol. 1994, 14:3230-3241.
4. Benini S., Manara M.C., Cerisano V., Perdichizzi S., Strammiello R., Serra M., Picci P., Scotlandi K. Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int. J. Cancer 2003, 108:358-366.
5. Blagosklonny M.V., Toretsky J., Bohen S., Neckers L. Mutant conformation of p53 translated invitro or invivo requires functional HSP90. Proc. Natl. Acad. Sci. 1996, 93:8379-8383.
6. Caldas-Lopes E., Cerchietti L., Ahn J.H., Clement C.C., Robles A.I., Rodina A., Moulick K., Taldone T., Gozman A., Guo Y., Wu N., de Stanchina E., White J., Gross S.S., Ma Y., Varticovski L., Melnick A., Chiosis G. Hsp90 inhibitor PU-H71, a multimodal inhibitor of malignancy, induces complete responses in triple-negative breast cancer models. Proc. Natl. Acad. Sci. 2009, 106:8368-8373.
7. Cerchietti L.C., Lopes E.C., Yang S.N., Hatzi K., Bunting K.L., Tsikitas L.A., Mallik A., Robles A.I., Walling J., Varticovski L., Shaknovich R., Bhalla K.N., Chiosis G., Melnick A. A purine scaffold Hsp90 inhibitor destabilizes BCL-6 and has specific antitumor activity in BCL-6-dependent B cell lymphomas. Nat. Med. 2009, 15:1369-1376.
8. Chou T.C. Drug combination studies and their synergy quantification using the Chou-Talalay method. Cancer Res. 2010, 70:440-446.
9. Chou, T.-C., Martin N. CompuSyn Software for Drug Combinations and for General Dose-Effect Analysis, and User's Guide 2007, ComboSyn, Inc., Paramus, NJ., (www.combosyn.com).
10. De Vito C., Riggi N., Cornaz S., Suvà M.-L., Baumer K., Provero P., Stamenkovic I. A TARBP2-dependent miRNA expression profile underlies cancer stem cell properties and provides candidate therapeutic reagents in Ewing sarcoma. Cancer Cell 2012, 21:807-821.
11. Erkizan H.V., Uversky V.N., Toretsky J.A. Oncogenic partnerships: EWS-FLI1 protein interactions initiate key pathways of Ewing's sarcoma. Clin. Cancer Res. 2010, 16:4077-4083.
12. Franken N.A.P., Rodermond H.M., Stap J., Haveman J., van Bree C. Clonogenic assay of cells invitro. Nat. Protoc. 2006, 1:2315-2319.
13. Fuchs B., Inwards C., Scully S.P., Janknecht R. hTERT is highly expressed in Ewing's sarcoma and activated by EWS-ETS oncoproteins. Clin. Orthop. Relat. Res. 2004, 64-68.
14. Garofalo C., Manara M.C., Nicoletti G., Marino M.T., Lollini P.L., Astolfi A., Pandini G., Lopez-Guerrero J.A., Schaefer K.L., Belfiore A., Picci P., Scotlandi K. Efficacy of and resistance to anti-IGF-1R therapies in Ewing's sarcoma is dependent on insulin receptor signaling. Oncogene 2011, 30:2730-2740.
15. Grier H.E., Krailo M.D., Tarbell N.J., Link M.P., Fryer C.J., Pritchard D.J., Gebhardt M.C., Dickman P.S., Perlman E.J., Meyers P.A., Donaldson S.S., Moore S., Rausen A.R., Vietti T.J., Miser J.S. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N.Engl. J. Med. 2003, 348:694-701.
16. He H., Zatorska D., Kim J., Aguirre J., Llauger L., She Y., Wu N., Immormino R.M., Gewirth D.T., Chiosis G. Identification of potent water soluble purine-scaffold inhibitors of the heat shock protein 90. J.Med. Chem. 2006, 49:381-390.
17. Hennessy B.T., Lu Y., Gonzalez-Angulo A.M., Carey M.S., Myhre S., Ju Z., Davies M.A., Liu W., Coombes K., Meric-Bernstam F., Bedrosian I., McGahren M., Agarwal R., Zhang F., Overgaard J., Alsner J., Neve R.M., Kuo W.-L., Gray J.W., Borresen-Dale A.-L., Mills G.B. A technical assessment of the utility of reverse phase protein arrays for the study of the functional proteome in non-microdissected human breast cancers. Clin. Proteom. 2010, 6:129-151.
18. Kauer M., Ban J., Kofler R., Walker B., Davis S., Meltzer P., Kovar H. A molecular function map of Ewing's sarcoma. PLoS ONE 2009, 4:e5415.
19. Kim S., Kang J., Hu W., Evers B.M., Chung D.H. Geldanamycin decreases Raf-1 and Akt levels and induces apoptosis in neuroblastomas. Int. J. Cancer 2002, 103:352-359.
20. Landuzzi L., De Giovanni C., Nicoletti G., Rossi I., Ricci C., Astolfi A., Scopece L., Scotlandi K., Serra M., Bagnara G.P., Nanni P., Lollini P.-L. The metastatic ability of Ewing's sarcoma cells is modulated by stem cell factor and by its receptor c-kit. Am. J. Pathol. 2000, 157:2123-2131.
21. Lesko E., Gozdzik J., Kijowski J., Jenner B., Wiecha O., Majka M. HSP90 antagonist, geldanamycin, inhibits proliferation, induces apoptosis and blocks migration of rhabdomyosarcoma cells invitro and seeding into bone marrow invivo. Anticancer Drugs 2007, 18:1173-1181.
22. Lin P.P., Brody R.I., Hamelin A.C., Bradner J.E., Healey J.H., Ladanyi M. Differential transactivation by alternative EWS-FLI1 fusion proteins correlates with clinical heterogeneity in Ewing's sarcoma. Cancer Res. 1999, 59:1428-1432.
23. López-Maderuelo M.D., Fernández-Renart M., Moratilla C., Renart J. Opposite effects of the Hsp90 inhibitor Geldanamycin: induction of apoptosis in PC12, and differentiation in N2A cells. FEBS Lett. 2001, 490:23-27.
24. Maki R.G., Kraft A.S., Scheu K., Yamada J., Wadler S., Antonescu C.R., Wright J.J., Schwartz G.K. A multicenter phase II study of bortezomib in recurrent or metastatic sarcomas. Cancer 2005, 103:1431-1438.
25. Martins A.S., Ordonez J.L., Garcia-Sanchez A., Herrero D., Sevillano V., Osuna D., Mackintosh C., Caballero G., Otero A.P., Poremba C., Madoz-Gurpide J., de Alava E. A pivotal role for heat shock protein 90 in Ewing sarcoma resistance to anti-insulin-like growth factor 1 receptor treatment: invitro and invivo study. Cancer Res. 2008, 68:6260-6270.
26. Martínez-Ramírez A., Rodríguez-Perales S., Meléndez B., Martínez-Delgado B., Urioste M., Cigudosa J.C., Benítez J. Characterization of the A673 cell line (Ewing tumor) by molecular cytogenetic techniques. Cancer Genet. Cytogenet. 2003, 141:138-142.
27. Marubayashi S., Koppikar P., Taldone T., Abdel-Wahab O., West N., Bhagwat N., Caldas-Lopes E., Ross K.N., Gönen M., Gozman A., Ahn J.H., Rodina A., Ouerfelli O., Yang G., Hedvat C., Bradner J.E., Chiosis G., Levine R.L. HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans. J.Clin. Invest. 2010, 120:3578-3593.
28. McCleese J.K., Bear M.D., Fossey S.L., Mihalek R.M., Foley K.P., Ying W., Barsoum J., London C.A. The novel HSP90 inhibitor STA-1474 exhibits biologic activity against osteosarcoma cell lines. Int. J. Cancer 2009, 125:2792-2801.
29. Miser J.S., Goldsby R.E., Chen Z., Krailo M.D., Tarbell N.J., Link M.P., Fryer C.J., Pritchard D.J., Gebhardt M.C., Dickman P.S., Perlman E.J., Meyers P.A., Donaldson S.S., Moore S.G., Rausen A.R., Vietti T.J., Grier H.E. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy - a report from the Children's oncology group. Pediatr. Blood Cancer 2007, 49:894-900.
30. Mitsiades C.S., Mitsiades N.S., McMullan C.J., Poulaki V., Kung A.L., Davies F.E., Morgan G., Akiyama M., Shringarpure R., Munshi N.C., Richardson P.G., Hideshima T., Chauhan D., Gu X., Bailey C., Joseph M., Libermann T.A., Rosen N.S., Anderson K.C. Antimyeloma activity of heat shock protein-90 inhibition. Blood 2006, 107:1092-1100.
31. Morozov A., Downey R.J., Healey J., Moreira A.L., Lou E., Franceschino A., Dogan Y., Leung R., Edgar M., LaQuaglia M., Maki R.G., Moore M.A.S. Benign mesenchymal stromal cells in human sarcomas. Clin. Cancer Res. 2010, 16:5630-5640.
32. Moulick K., Ahn J.H., Zong H., Rodina A., Cerchietti L., Gomes DaGama E.M., Caldas-Lopes E., Beebe K., Perna F., Hatzi K., Vu L.P., Zhao X., Zatorska D., Taldone T., Smith-Jones P., Alpaugh M., Gross S.S., Pillarsetty N., Ku T., Lewis J.S., Larson S.M., Levine R., Erdjument-Bromage H., Guzman M.L., Nimer S.D., Melnick A., Neckers L., Chiosis G. Affinity-based proteomics reveal cancer-specific networks coordinated by Hsp90. Nat. Chem. Biol. 2011, 7:818-826.
33. Nimmanapalli R., O'Bryan E., Bhalla K. Geldanamycin and its analogue 17-allylamino-17-demethoxygeldanamycin lowers Bcr-Abl levels and induces apoptosis and differentiation of Bcr-Abl-positive human leukemic blasts. Cancer Res. 2001, 61:1799-1804.
34. Ohali A., Avigad S., Zaizov R., Ophir R., Horn-Saban S., Cohen I.J., Meller I., Kollender Y., Issakov J., Yaniv I. Prediction of high risk Ewing's sarcoma by gene expression profiling. Oncogene 2004, 23:8997-9006.
35. Ottaviano L., Schaefer K.-L., Gajewski M., Huckenbeck W., Baldus S., Rogel U., Mackintosh C., de Alava E., Myklebost O., Kresse S.H., Meza-Zepeda L.A., Serra M., Cleton-Jansen A.-M., Hogendoorn P.C.W., Buerger H., Aigner T., Gabbert H.E., Poremba C. Molecular characterization of commonly used cell lines for bone tumor research: a trans-European EuroBoNet effort. Genes Chromosom. Cancer 2010, 49:40-51.
36. Pappo A.S., Patel S.R., Crowley J., Reinke D.K., Kuenkele K.P., Chawla S.P., Toner G.C., Maki R.G., Meyers P.A., Chugh R., Ganjoo K.N., Schuetze S.M., Juergens H., Leahy M.G., Geoerger B., Benjamin R.S., Helman L.J., Baker L.H. R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II sarcoma alliance for research through collaboration study. J.Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 2011, 29:4541-4547.
37. Peron M., Bonvini P., Rosolen A. Effect of inhibition of the ubiquitin-proteasome system and Hsp90 on growth and survival of Rhabdomyosarcoma cells invitro. BMC Cancer 2012, 12:233.
38. RCoreTeam, n.d. R: a Language and Environment for Statistical Computing, 2012 ed. R Foundation for Statistical Computing, Vienna, Austria.
39. Roue G., Perez-Galan P., Mozos A., Lopez-Guerra M., Xargay-Torrent S., Rosich L., Saborit-Villarroya I., Normant E., Campo E., Colomer D. The Hsp90 inhibitor IPI-504 overcomes bortezomib resistance in mantle cell lymphoma invitro and invivo by down-regulation of the prosurvival ER chaperone BiP/Grp78. Blood 2011, 117:1270-1279.
40. Schmid I., Krall W.J., Uittenbogaart C.H., Braun J., Giorgi J.V. Dead cell discrimination with 7-amino-actinomycin D in combination with dual color immunofluorescence in single laser flow cytometry. Cytometry 1992, 13:204-208.
41. Scotlandi K., Benini S., Nanni P., Lollini P.L., Nicoletti G., Landuzzi L., Serra M., Manara M.C., Picci P., Baldini N. Blockage of insulin-like growth factor-I receptor inhibits the growth of Ewing's sarcoma in athymic mice. Cancer Res. 1998, 58:4127-4131.
42. Scotlandi K., Benini S., Sarti M., Serra M., Lollini P.-L., Maurici D., Picci P., Manara M.C., Baldini N. Insulin-like growth factor I receptor-mediated circuit in Ewing's sarcoma/peripheral neuroectodermal tumor: a possible therapeutic target. Cancer Res. 1996, 56:4570-4574.
43. Silvany R.E., Eliazer S., Wolff N.C., Ilaria R.L. Interference with the constitutive activation of ERK1 and ERK2 impairs EWS/FLI-1-dependent transformation. Oncogene 2000, 19:4523-4530.
44. Smith M.A., Seibel N.L., Altekruse S.F., Ries L.A., Melbert D.L., O'Leary M., Smith F.O., Reaman G.H. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J.Clin. Oncol. Official J. Am. Soc. Clin. Oncol. 2010, 28:2625-2634.
45. Sohn E.J., Li H., Reidy K., Beers L.F., Christensen B.L., Lee S.B. EWS/FLI1 oncogene activates caspase 3 transcription and triggers apoptosis invivo. Cancer Res. 2010, 70:1154-1163.
46. Takahashi A., Higashino F., Aoyagi M., Yoshida K., Itoh M., Kyo S., Ohno T., Taira T., Ariga H., Nakajima K., Hatta M., Kobayashi M., Sano H., Kohgo T., Shindoh M. EWS/ETS fusions activate telomerase in Ewing's tumors. Cancer Res. 2003, 63:8338-8344.
47. Ulaner G.A., Hoffman A.R., Otero J., Huang H.-Y., Zhao Z., Mazumdar M., Gorlick R., Meyers P., Healey J.H., Ladanyi M. Divergent patterns of telomere maintenance mechanisms among human sarcomas: sharply contrasting prevalence of the alternative lengthening of telomeres mechanism in Ewing's sarcomas and osteosarcomas. Genes Chromosom. Cancer 2004, 41:155-162.
48. van Engeland M., Ramaekers F.C., Schutte B., Reutelingsperger C.P. A novel assay to measure loss of plasma membrane asymmetry during apoptosis of adherent cells in culture. Cytometry 1996, 24:131-139.
49. Weigel B.J., Blaney S.M., Reid J.M., Safgren S.L., Bagatell R., Kersey J., Neglia J.P., Ivy S.P., Ingle A.M., Whitesell L., Gilbertson R.J., Krailo M., Ames M., Adamson P.C. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children's oncology group study. Clin. Cancer Res. 2007, 13:1789-1793.
50. Whitesell L., Lindquist S.L. HSP90 and the chaperoning of cancer. Nat. Rev. Cancer 2005, 5:761-772.